Cellyxa Therapeutics is targeting the expansive global metastatic solid tumor market, with an initial strategic focus on high-risk breast cancers and large unmet needs in TNBC and ER+ indications. We are positioned to transition from a discovery platform to a clinical-stage entity with a high-barrier-to-entry asset portfolio.

We are actively engaging with strategic partners and venture capital to fund our next critical milestones, including IND-enabling studies, manufacturing scale-up, and the finalization of our companion diagnostic strategy.

Authorized investors and strategic partners can request access to our secure data room for non-confidential corporate presentations, executive summaries, and detailed pipeline information.